Cheng Deng Sells 9,836 Shares of Zepp Health (NYSE:ZEPP) Stock

Zepp Health Corporation Sponsored ADR (NYSE:ZEPP) CFO Cheng Deng sold 9,836 shares of the company’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $4.61, for a total transaction of $45,343.96. Following the completion of the transaction, the chief financial officer owned 114,539 shares of the company’s stock, valued at $528,024.79. This trade represents a 7.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Zepp Health Trading Up 9.3%

NYSE:ZEPP opened at $5.17 on Wednesday. The company has a 50-day moving average price of $9.38 and a 200-day moving average price of $16.79. Zepp Health Corporation Sponsored ADR has a 12 month low of $2.56 and a 12 month high of $61.85. The company has a current ratio of 0.88, a quick ratio of 0.67 and a debt-to-equity ratio of 0.21. The stock has a market cap of $75.90 million, a price-to-earnings ratio of -2.05 and a beta of 1.78.

Institutional Trading of Zepp Health

A number of hedge funds and other institutional investors have recently modified their holdings of ZEPP. FIL Ltd purchased a new position in Zepp Health during the 4th quarter valued at about $16,858,000. Millennium Management LLC grew its holdings in Zepp Health by 49.1% in the fourth quarter. Millennium Management LLC now owns 366,826 shares of the company’s stock worth $9,882,000 after purchasing an additional 120,750 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in Zepp Health by 17.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 295,967 shares of the company’s stock worth $7,974,000 after purchasing an additional 44,619 shares during the period. Balyasny Asset Management L.P. grew its holdings in Zepp Health by 46.9% in the fourth quarter. Balyasny Asset Management L.P. now owns 202,775 shares of the company’s stock worth $5,463,000 after purchasing an additional 64,692 shares during the period. Finally, UBS Group AG increased its stake in shares of Zepp Health by 16,412.0% during the third quarter. UBS Group AG now owns 181,302 shares of the company’s stock valued at $8,300,000 after purchasing an additional 180,204 shares in the last quarter. 52.61% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have weighed in on ZEPP shares. Wall Street Zen downgraded Zepp Health from a “hold” rating to a “sell” rating in a report on Saturday. Fundamental Research set a $56.28 target price on Zepp Health and gave the stock a “buy” rating in a research report on Wednesday, April 22nd. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $56.28.

Zepp Health Company Profile

Zepp Health Corp is a technology company specializing in the design, development and sale of smart wearable devices and health management solutions. Through its flagship Amazfit brand and the Zepp software ecosystem, the company offers a range of products—including smartwatches, fitness bands, smart scales and health-oriented mobile applications—designed to track key biometric data such as heart rate, sleep patterns, blood oxygen levels and activity metrics. Zepp Health’s integrated platform enables users to monitor wellness and fitness goals while leveraging cloud-based analytics for personalized insights.

At the core of Zepp Health’s offering is its Zepp cloud platform, which aggregates and analyzes data collected from its hardware lineup.